Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents

Research output: Contribution to journalArticle

Abstract

Introduction: Heat-shock proteins (HSPs) are highly conserved, stress-induced proteins that function as chaperones, stabilizing proteins and delivering peptides. Tumor-derived HSP peptide complexes (HSPPCs) induced immunity against several malignancies in preclinical models, exhibiting activity across tumor types. Areas covered: HSPPC-based vaccination showed clinical activity in subsets of patients with different malignancies (e.g., gastric, colorectal, pancreatic, ovarian cancer, and glioblastoma). In Phase III clinical trials for advanced melanoma and renal cell carcinoma patients, HSPPC-based vaccine demonstrated an excellent safety profile, thus emerging as a flexible tumor- and patient-specific therapeutic approach. Expert opinion: Melanoma, renal clear cell carcinoma, and glioblastoma are among suitable targets for HSP-based treatment as demonstrated by immune responses and clinical activity observed in subsets of patients, mainly those with early stage of disease and limited tumor burden. In order to further improve clinical activity, combinations of HSPPC-based vaccines with mutation-driven therapies, antiangiogenic agents, or immunomodulating monoclonal antibodies should be tested in controlled clinical trials.

Original languageEnglish
Pages (from-to)955-967
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume14
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Heat-Shock Proteins
Immunotherapy
Melanoma
Tumors
Peptides
Neoplasms
Glioblastoma
Renal Cell Carcinoma
Vaccines
Cells
Therapeutics
Phase III Clinical Trials
Angiogenesis Inhibitors
Controlled Clinical Trials
Expert Testimony
Tumor Burden
Pancreatic Neoplasms
Ovarian Neoplasms
Immunity
Stomach

Keywords

  • Heat-shock protein
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Cite this

@article{4465c7c7643a44aeb5cc7d581e33b639,
title = "Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents",
abstract = "Introduction: Heat-shock proteins (HSPs) are highly conserved, stress-induced proteins that function as chaperones, stabilizing proteins and delivering peptides. Tumor-derived HSP peptide complexes (HSPPCs) induced immunity against several malignancies in preclinical models, exhibiting activity across tumor types. Areas covered: HSPPC-based vaccination showed clinical activity in subsets of patients with different malignancies (e.g., gastric, colorectal, pancreatic, ovarian cancer, and glioblastoma). In Phase III clinical trials for advanced melanoma and renal cell carcinoma patients, HSPPC-based vaccine demonstrated an excellent safety profile, thus emerging as a flexible tumor- and patient-specific therapeutic approach. Expert opinion: Melanoma, renal clear cell carcinoma, and glioblastoma are among suitable targets for HSP-based treatment as demonstrated by immune responses and clinical activity observed in subsets of patients, mainly those with early stage of disease and limited tumor burden. In order to further improve clinical activity, combinations of HSPPC-based vaccines with mutation-driven therapies, antiangiogenic agents, or immunomodulating monoclonal antibodies should be tested in controlled clinical trials.",
keywords = "Heat-shock protein, Immunotherapy, Melanoma",
author = "Giulio Tosti and Emilia Cocorocchio and Elisabetta Pennacchioli and Ferrucci, {Pier Francesco} and Alessandro Testori and Chiara Martinoli",
year = "2014",
doi = "10.1517/14712598.2014.902928",
language = "English",
volume = "14",
pages = "955--967",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents

AU - Tosti, Giulio

AU - Cocorocchio, Emilia

AU - Pennacchioli, Elisabetta

AU - Ferrucci, Pier Francesco

AU - Testori, Alessandro

AU - Martinoli, Chiara

PY - 2014

Y1 - 2014

N2 - Introduction: Heat-shock proteins (HSPs) are highly conserved, stress-induced proteins that function as chaperones, stabilizing proteins and delivering peptides. Tumor-derived HSP peptide complexes (HSPPCs) induced immunity against several malignancies in preclinical models, exhibiting activity across tumor types. Areas covered: HSPPC-based vaccination showed clinical activity in subsets of patients with different malignancies (e.g., gastric, colorectal, pancreatic, ovarian cancer, and glioblastoma). In Phase III clinical trials for advanced melanoma and renal cell carcinoma patients, HSPPC-based vaccine demonstrated an excellent safety profile, thus emerging as a flexible tumor- and patient-specific therapeutic approach. Expert opinion: Melanoma, renal clear cell carcinoma, and glioblastoma are among suitable targets for HSP-based treatment as demonstrated by immune responses and clinical activity observed in subsets of patients, mainly those with early stage of disease and limited tumor burden. In order to further improve clinical activity, combinations of HSPPC-based vaccines with mutation-driven therapies, antiangiogenic agents, or immunomodulating monoclonal antibodies should be tested in controlled clinical trials.

AB - Introduction: Heat-shock proteins (HSPs) are highly conserved, stress-induced proteins that function as chaperones, stabilizing proteins and delivering peptides. Tumor-derived HSP peptide complexes (HSPPCs) induced immunity against several malignancies in preclinical models, exhibiting activity across tumor types. Areas covered: HSPPC-based vaccination showed clinical activity in subsets of patients with different malignancies (e.g., gastric, colorectal, pancreatic, ovarian cancer, and glioblastoma). In Phase III clinical trials for advanced melanoma and renal cell carcinoma patients, HSPPC-based vaccine demonstrated an excellent safety profile, thus emerging as a flexible tumor- and patient-specific therapeutic approach. Expert opinion: Melanoma, renal clear cell carcinoma, and glioblastoma are among suitable targets for HSP-based treatment as demonstrated by immune responses and clinical activity observed in subsets of patients, mainly those with early stage of disease and limited tumor burden. In order to further improve clinical activity, combinations of HSPPC-based vaccines with mutation-driven therapies, antiangiogenic agents, or immunomodulating monoclonal antibodies should be tested in controlled clinical trials.

KW - Heat-shock protein

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84902194486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902194486&partnerID=8YFLogxK

U2 - 10.1517/14712598.2014.902928

DO - 10.1517/14712598.2014.902928

M3 - Article

C2 - 24670226

AN - SCOPUS:84902194486

VL - 14

SP - 955

EP - 967

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -